Woodmont Investment Counsel LLC Increases Position in Moderna, Inc. (NASDAQ:MRNA)

Woodmont Investment Counsel LLC boosted its position in Moderna, Inc. (NASDAQ:MRNA) by 63.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 21,188 shares of the company’s stock after acquiring an additional 8,218 shares during the period. Woodmont Investment Counsel LLC’s holdings in Moderna were worth $1,416,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of MRNA. Cedar Wealth Management LLC increased its stake in Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after purchasing an additional 90 shares during the last quarter. Commerzbank Aktiengesellschaft FI raised its holdings in shares of Moderna by 1.7% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock worth $660,000 after purchasing an additional 93 shares during the period. CVA Family Office LLC lifted its stake in shares of Moderna by 21.6% in the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company’s stock valued at $64,000 after purchasing an additional 96 shares in the last quarter. Claro Advisors LLC grew its holdings in shares of Moderna by 2.0% during the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock worth $659,000 after purchasing an additional 108 shares during the period. Finally, McAdam LLC increased its position in Moderna by 1.1% during the 2nd quarter. McAdam LLC now owns 11,075 shares of the company’s stock worth $1,315,000 after purchasing an additional 117 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Moderna news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,184 shares of company stock valued at $238,531. Insiders own 15.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and decreased their price target for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. UBS Group reduced their price target on Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Piper Sandler lowered their price objective on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, September 13th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Friday, September 13th. Finally, TD Cowen dropped their price target on shares of Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research note on Friday, September 13th. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Moderna has an average rating of “Hold” and an average target price of $94.00.

Moderna Trading Down 2.8 %

NASDAQ MRNA opened at $51.81 on Thursday. The firm has a market capitalization of $19.92 billion, a PE ratio of -3.37 and a beta of 1.69. Moderna, Inc. has a one year low of $49.60 and a one year high of $170.47. The company has a 50-day simple moving average of $63.00 and a 200-day simple moving average of $99.97. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.